Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Operations: 2013-2019

Historic Cash from Operations for Soleno Therapeutics (SLNO) over the last 6 years, with Dec 2019 value amounting to -$5.1 million.

  • Soleno Therapeutics' Cash from Operations fell 35.87% to -$5.1 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$17.4 million, marking a year-over-year decrease of 48.72%. This contributed to the annual value of -$69.1 million for FY2024, which is 177.06% down from last year.
  • Soleno Therapeutics' Cash from Operations amounted to -$5.1 million in Q4 2019, which was down 7.57% from -$4.7 million recorded in Q3 2019.
  • In the past 5 years, Soleno Therapeutics' Cash from Operations ranged from a high of -$1.8 million in Q1 2015 and a low of -$5.1 million during Q4 2019.
  • Moreover, its 3-year median value for Cash from Operations was -$2.9 million (2017), whereas its average is -$3.3 million.
  • As far as peak fluctuations go, Soleno Therapeutics' Cash from Operations tumbled by 255.40% in 2015, and later surged by 45.21% in 2017.
  • Over the past 5 years, Soleno Therapeutics' Cash from Operations (Quarterly) stood at -$3.4 million in 2015, then rose by 20.41% to -$2.7 million in 2016, then dropped by 1.60% to -$2.7 million in 2017, then tumbled by 36.75% to -$3.7 million in 2018, then slumped by 35.87% to -$5.1 million in 2019.
  • Its last three reported values are -$5.1 million in Q4 2019, -$4.7 million for Q3 2019, and -$3.9 million during Q2 2019.